Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LI.b

Valvular heart disease and/or dysfunction

Publications

Gu H, Luck S, Carroll PV, Powrie J, Chambers J

Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias?

Clinical endocrinology 2011 May;74;608-10 — 2011 May — 608-10

Andersohn F, Garbe E

Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.

Movement disorders : official journal of the Movement Disorder Society 2009 Jan 15;24;129-33 — 2009 Jan 15 — 129-33

Kim JY, Chung EJ, Park SW, Lee WY

Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.

Movement disorders : official journal of the Movement Disorder Society 2006 Aug;21;1261-4 — 2006 Aug — 1261-4

Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ

Fibrotic valvular heart disease subsequent to bromocriptine treatment.

Cardiology in review 2002 Nov-Dec;10;334-6 — 2002 Nov-Dec — 334-6